Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-0120 multiple ascending dose in healthy volunteers and hyperuricemia patients
CTR20182076Phase 2Completed
- Sponsor
- EpimAb Biotherapeutics
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of darbinurad in hyperuricemia, gout, sponsored by EpimAb Biotherapeutics. Started May 2019; status: completed.
02
Drugs
darbinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on CTR20182076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182076.